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Results of Systematic Nodal Dissection in Typical
and Atypical Carcinoid Tumors of the Lung
Alain Wurtz, MD,* Lotfi Benhamed, MD,* Massimo Conti, MD,* Brigitte Bouchindhomme, MD,†
and Henri Porte, MD, PhD*
Background: To determine the lymphatic spread frequency and
location in patients, who underwent lung resection for carcinoid
tumors, associated with systematic nodal dissection.
Methods: From January 1998 to June 2007, 54 patients underwent
anatomic lung resection associated with systematic nodal dissection
for tumors classified as typical (TC) or atypical carcinoid according
to 1999 World Health Organization criteria. The number and loca-
tion of the resected lymph nodes were specified. All patients were
followed up.
Results: All patients underwent complete resection (R0) that were
anatomic in 32 patients (59.2%), and associated with a bronchop-
lastic procedure in 22 (40.8%). Low morbidity was related to
lymphadenectomy. The mean number of resected lymph nodes was
of 18 (range, 7–44) per patient, which pathologic studies demon-
strated lymphatic spread in 10 patients (18.5%). In the TC group
(n  42) 2 patients were classified N1 (4.8%) and 4 N2 (9.5%). In
the atypical group (n  12) 2 patients were classified N1 (16.6%)
and 2 N2 (16.6%).
Five of the 6 N2 patients showed a single skip metastasis not
discovered by preoperative evaluation (83.3%).
The lymphatic spread was correlated with age 35 years
(p  0.01) and a tumor size 3 cm (p  0.002).
Median follow-up was 57 months. Nine patients with lym-
phatic spread are disease free and one died from metastatic disease
at 52 months.
Conclusion: Systematic nodal dissection showed a high frequency
of unpredictable lymphatic spread, mainly in the TC group. This
procedure is mandatory to treat carcinoids in a curative intent.
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Carcinoid tumors of the lung are uncommon, constituting1 to 2% of all pulmonary neoplasms.1 They have a
neuroendocrine differentiation, are associated with relatively
slow growth and generally show a favorable outcome. In
1972 Arrigoni et al.2 classified these tumors into two distinc-
tive forms: typical (TC) and atypical carcinoids (AC). This
classification has continued to evolve and Warren et al.3
proposed in 1985 new criteria to separate carcinoids from
other neuroendocrine neoplasms. They were later modified
by Travis et al.4 and in 1999 the World Health Organization
(WHO) reduced confusion and established a definitive clas-
sification5 based on Travis’s works, unchanged in 20046
(Table 1). Therefore, the spectrum of neuroendocrine tumors
includes four entities of increasing malignancy: TC, AC or
well differentiated carcinoma, high grade large-cell neuroen-
docrine carcinoma and small-cell carcinoma.
Carcinoid tumors have a propensity to develop in the
right lung7 and are mainly located in the major bronchi.8
Approximately 30% of carcinoids are located in the periphery
of the lungs. Endocrine manifestations are rare and may
reveal a peripheral tumor, especially carcinoid and Cushing’s
syndromes.1,8 From literature, AC presents more nodal me-
tastasis and higher recurrence rate than does TC. However,
the lymphatic spread frequency of carcinoids is difficult to
estimate.
First, the classification into two distinctive forms (TC
and AC) has changed over the years. Consequently, in series
including neuroendocrine tumors classified according to the
old classifications, before the 1999 WHO criteria, they are
some overlaps among the different entities, leading to signif-
icant misleading factors in the lymphatic spread study.9–21
Furthermore, other series including TC and AC classi-
fied according to the new criteria7,22–29 lack of details7,27 or
homogeneity23,24,28,29 about the lymphadenectomy performed
during surgery. In this field, the aim of our study was to
precise the frequency and location of nodal metastasis ac-
cording to demographic data, macroscopic and microscopic
aspect of the carcinoid tumors of the lung in patients who
underwent surgical resection including systematic nodal dis-
section.
PATIENTS AND METHODS
The study was approved by the institutional review
board and from 1998 to June 2007, 54 patients (42 TC and 12
AC) were included. There were 31 women and 23 men aged
from 11 to 75 years (mean 45  16.3 years).
Thirty-eight patients (70.4%) were symptomatic at pre-
sentation including recurrent obstructive pneumonia (n 
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14), hemoptysis (n  10), persistent cough (n  9), asthma
(n  3), Cushing’s syndrome (n  2).
Patients underwent routine preoperative evaluation, in-
cluding physical examination, chest and upper abdominal
computed tomography. Positron emission tomography was
performed in 11 patients and was positive in 7 (63.6%),
without significant fixation in hilar or mediastinal lymph node
in all of them. Fiber optic bronchoscopy was performed in all
patients and rigid bronchoscopy in 14, for proper histologic
diagnosis in 10, and to restore airway patency prior to surgery
in 4. Tumors visualized at bronchoscopy were classified as
central (n  48), 89%. Biopsies were performed in 37
patients and 3 of them (5.7%) who underwent biopsies with
fiber optic bronchoscopy before surgery were misdiagnosed:
one as a well differentiated adenocarcinoma and two as a
small-cell carcinoma. (The later received chemo-radiotherapy
before referral to our institution).
The remaining 6 tumors (11%) were classified as pe-
ripheral and transthoracic needle biopsy was never performed
in these cases. Lastly, 34 patients (63%) were correctly
diagnosed prior to surgery. No evidence of mediastinal
lymphadenopathy was identified in any patient, by computed
or positron emission tomography, so that mediastinoscopy
was never performed.
Surgical Management
All patients underwent anatomic resection. For cen-
trally located tumors, bronchoplastic procedures were con-
sidered to spare the distal functional lung tissue11 and formal
anatomic resections were performed mainly when distal pa-
renchyma was destroyed, due to chronic obstruction. Frozen
section analysis of the bronchial margins were routinely
performed. In case of peripheral tumors, segmentectomy or
lobectomy was considered, according to tumor location.
The resection of hilar, intrapulmonary, and mediastinal
lymph nodes, including at least three mediastinal stations, one
of which being station seven,30 was routinely performed even
in peripheral tumors.
Operative Complications
Operative complications were classified as pulmonary
(air leak 7 days, pneumonia, pleural effusions, atelectasis),
cardiovascular complications (myocardial infarction, arrhyth-
mia, pulmonary embolism) and complications related to sys-
tematic nodal dissection (recurrent nerve palsy, chylothorax).
Operative mortality included the patients who died during
hospitalization.
Pathologic Data
Pathology slide blocks of six patients who underwent
surgical resection before 1999 where reviewed by a pathol-
ogist with a special interest in lung tumors, using the criteria
outlined by Travis.4 Overall, all the tumors were classified
according to the new 1999 WHO criteria for neuroendocrine
tumors.5,6 (Table 1) The size, location, macroscopic and
microscopic aspects were studied to classify tumors as in-
traluminal (tumor invading the overlying mucosa), mural
(tumor invading the bronchus wall) or iceberg tumor (tumor
with an extra wall component).
Lymphadenectomy’s specimens were analyzed with
special attention to the number and location of the metastatic
and non metastatic resected lymph nodes, according to the
American Thoracic Society map.31 Definitive staging was
determined according to the Revisited International Clinical
Staging System.32
Follow-Up
All patients were followed up by physical examination
and chest radiograph 3 months after the operation, fiber optic
bronchoscopy, chest and upper abdominal computed tomog-
raphy at 6 months, and then every year. Survival and tumor
recurrence were measured from the date of operation.
Statistical Analysis
Patients were evaluated for demographic data, tumor
location, surgical, and pathologic variables. The distributions
were compared using the 2 test or Fisher’s exact test for
discrete variables and unpaired Student t test for continuous
variables. Odds ratio and 95% confidence intervals were
calculated to assess the relationship between each variable
and the lymphatic spread.
Quantitative data were expressed as the mean  SD.
Two sets of survival curves - one based on the pathologic
diagnosis and another one based on lymphatic spread - were
generated using the Kaplan-Meier method, and compared
with the log-rank test. A p value lower than 0.05 was considered
statistically significant. All data were analyzed with the Statis-
tical Package for Social Sciences 15.0.1 software.
RESULTS
A complete resection (R0) was performed in all pa-
tients, including anatomic resection in 32 of them (59.2%):
lobectomy (n  18), bilobectomy (n  10), standard pneu-
monectomy (n  2), segmentectomy (n  2) and a broncho-
plastic procedure in 22 of them (40.8%) : sleeve upper
lobectomy (n  15), sleeve middle or lower lobectomy (n 
3), right pneumonectomy with carinal resection (n  3), left
main stem bronchial sleeve resection (n  1).33
A mean of 3.55  0.77 (range, 3–5) lymph node
stations were dissected and 18  8.23 nodes (range, 7–44)
resected per patient.
The postoperative course was uneventful in 38 patients,
including both with ACTH-secreting AC who became eucor-
tisolemic immediately after operation (70.4%). Fifteen pa-
tients presented postoperative complications (morbidity rate:
27.8%), related to lung resection in 7 (13%), including
prolonged air leaks (n  4) or pleural effusion (n  1)
TABLE 1. 1999–2004 World Health Organization Criteria
for Carcinoid Tumors of the Lung Classification
Typical carcinoid
A tumor with carcinoid morphology with fewer than 2 mitoses per
2 mm2 (10 high power fields) and lacking necrosis.
Atypical carcinoid
A tumor with carcinoid morphology with 2–10 mitoses per 2 mm2 (10
high power fields) and or foci of necrosis.
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requiring prolonged chest tube drainage, pneumonia (n  1)
requiring prolonged mechanical ventilation, atelectasis re-
quiring fiberoptic desobstruction (n  1).
In 8 cases (14.8%), postoperative complications were
related to lymphadenectomy: chylothorax (n  1, 1.8%),
which pharmacologically recovered; recurrent nerve palsy
(n 7, 13%) with total symptom’s regression 3 months later,
in all but one case.
Ninety days after resection, a 74-year-old patient, who
underwent right pneumonectomy for a 9 cm diameter hilar
TC, died of adult respiratory distress syndrome (in hospital
mortality rate, 1.8%).
Pathologic Findings
According to new WHO criteria, 42 tumors were clas-
sified as TC and 12 as AC, which size varied from 0.5 to 9 cm
(mean 2, 1.6 cm). They were located in the right lung in 33
cases (61%) and in the left lung in 21 cases (39%). The
location, the macroscopic and microscopic aspect of the
carcinoid tumors are summarized in Table 2.
Among the TC group (n  42), 2 patients were classi-
fied N1 (4.8%) and 4 N2 (9.5%). Among the AC group (n 
12), 2 patients were classified N1 (16.6%) and 2 N2 (16.6%).
In both groups a single skip metastasis was found in 5 of 6 N2
patients (83.3%) (Table 3). The definitive staging of 54
patients is summarized in Table 4.
Follow-Up
No patient was lost for follow-up, with a 57.24  29.9
months (range, 9–124) median time of observation. In the TC
group, 2 N0 patients died of metastatic disease respectively at
36 and 76 months (mortality rate, 4.8%) and there was
another death not related to the disease. Among survivors
(n  39), one patient is alive with liver metastasis that
appeared 12 months after surgery. In the AC group, all but
one patient are alive and disease free. A 79-year-old woman
(Table 3, patient n 7) who showed multiple nodal metastasis,
died of metastatic disease at 52 months (mortality rate, 8.3%).
Overall survival was 50 out of 54 patients (92.6%).
Statistical Analysis
Significantly higher frequency of lymphatic spread was
observed in patients aged 35 years (p  0.01, Odds Ratio
7.95% CI 1.5–31.8) and tumor size 3 cm (p  0.002, Odds
Ratio 12.3, 95% CI 2.5–59.6). No further relationship was
demonstrated between lymphatic spread and sex, tumor lo-
cation, macroscopic and microscopic aspect (TC or AC).
Kaplan-Meier survival and statistical comparative anal-
ysis did not show any difference according to histologic type
(p  0.264, Figure 1) and nodal status (p  0.518, Figure 2).
DISCUSSION
The real frequency of lymphatic spread in carcinoid
tumors of the lung is difficult to estimate and we here report
a series carried out to answer the question, by studying the
number and location of nodal metastatis. Indeed, all articles
before 1999 are inaccurate for this purpose, including carci-
noids classified according to the old classifications2,3 leading
to overlaps among the different entities (TC, AC and high-
grade large-cell neuroendocrine carcinoma).9–21 In other
series including newly classified carcinoids, the lymphad-
enectomy was not described7,27 or heterogeneously per-
formed.23,24,28,29 In a retrospective series of 517 carcinoids
that specifically addressed the outcome in patients presenting
with lymphatic spread,34 the low percentage of lymph node
TABLE 2. Location, Macroscopic and Microscopic Aspect of
Carcinoid Tumors of the Lung
Location Macroscopic and
Microscopic Aspect TC (42) AC (12) Total %
Central 39 9 89
Endoluminal 12 0 22.2
Mural 11 1 22.2
Iceberg 16 7 44.6
Peripheral 3 3 11
TC, typical carcinoid; AC, atypical carcinoid.
TABLE 3. Lymphatic Spread
Age
yr Sex
Macroscopic Aspect
(Tumor Size)
Procedure (Number
of Resected Lymph
Nodes)
Hilar and Intrapulmonary
Nodal Status (Location)
Mediastinal Nodal
Status (Location)
Single Skip
Metastasis
TNM
Classification
Typical Carcinoids with Lymphatic Spread (6/42:14.3%)
1 32 M Mural (3 cm) SRUL (12) 2N  9N–; 1N  (4R)  T2N2M0
2 59 M Iceberg tumor (3.8 cm) RLL (11) 2N  8N–; 1N  (7)  T2N2M0
3 29 M Endoluminal (1.9 cm) SRUL (20) 2N–; 1N  (11R) 17N  – T1N1MO
4 15 F Endoluminal (0.7 cm) RLL, ML (24) 4N  19 N–; 1N  (8R)  T1N2MO
5 49 F Iceberg tumor (4.5cm) SLUL (10) 3N  6N –; 1N (6L)  T2N2MO
6 20 F Iceberg tumor (5 cm) RLL, ML (31) 6N–; 1N (11R) 24 N  – T2N1MO
Atypical carcinoids with lymphatic spread (4/12:33.3%)
7 71 F Iceberg tumor (6 cm) LP (13) 2N–; 1N (10L) 2N–; 8N (4L, 7) – T2N2M0
8 34 F Peripheral (1.5 cm) LUL (9) 2N 7N  – T1N1M0
9 22 F Mural (3 cm) SRUL (23) 8N  14N–; 1N (4R)  T2N2M0
10 28 M Iceberg tumor (3.5 cm) SRP (41) 14N–; 2N  (10R, 11R) 25N  – T4N1M0
M, male; F, female; SRUL, sleeve right upper lobectomy; RLL, right lower lobectomy; ML, middle lobectomy; SLUL, sleeve left upper lobectomy; LP, left pneumonectomy;
LUL, left upper lobectomy; SRP, sleeve right pneumonectomy; N , no nodal metastasis; N , nodal metastasis; TNM, tumor, node, metastasis.
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metastases (5.99%) raises some doubt regarding the effec-
tiveness and the completeness of lymphadenectomy.25 Fur-
thermore, there was no information about the lymphatic
spread distribution between TC and AC respectively. Only
Cardillo et al.25 and Mineo et al.26 reported relevant series in
which all patients underwent formal lung resection associated
with systematic nodal dissection (Table 5).
In Cardillo’s series reporting 163 patients, the mean
number of resected lymph nodes was specified (12  7 per
patient). In the TC group (n  121) the percentage of
lymphatic spread was 11.6% (14 N1) and 63.2% in the AC
group (n  42), with 18 N1 and 9 N2.25 Furthermore, the
pathologic diagnosis of nodal metastasis was increased by
Mineo et al.,26 who emphasized the relevance of microme-
tastasis detection by immunohistochemical techniques: from
17 to 27.6% increase in TC group and from 50 to 87.5%
increase in AC group. With a lymphatic spread of 14.3% in
the TC group and 33.3% in the AC group (p  0.05) we did
not confirm the sparse data from literature.
In this field, literature (Table 5) shows a small percent-
age (mean 2.3, range, 0–5.3%) of N2 patients in TC group:
that was rather higher in our experience i.e., 4 N2 patients
(9.5%), all with a single skip metastasis that could have been
resected only after a complete clearance of the mediastinal
stations. In AC group, the higher percentage of N2 patients
(mean 17.9, range, 11.6–25%), is confirmed by our study: 2 N2
patients (16.6%) with a single skip metastasis in one (Table 5).
Another issue concerns the lymphatic spread predict-
ability. El Jamal et al.22 did not find any correlation between
tumor size and lymphatic spread risk. However, in our expe-
rience a tumor size 3 cm was significantly correlated with
a lymphatic spread (p 0.01) and age35 years (p 0.002)
and we did not find any correlation between location, mac-
roscopic or microscopic aspect (TC or AC) and lymphatic
spread risk. Nonetheless, in Cardillo’s series the difference in
lymphatic spread between TC and AC (11.57 versus 64.28%)
was highly significant (p  0.0001).
Risks and Benefits of Surgery Including
Systematic Nodal Dissection
The surgical strategy to resect carcinoids is lung pres-
ervation whenever possible. Out of 54 patients, 22 broncho-
FIGURE 1. Kaplan-Meier curves:
survival in patients comparing
those with typical carcinoids to
those with atypical carcinoids; Log-
rank p  0.264. AC, atypical carci-
noid; TC, typical carcinoid.
TABLE 4. TNM Classification According to the Revisited
International Clinical Staging System
Stage (%) TC AC Total
I (76)
T1N0M0 28 7 35
T2N0M0 6 — 6
II (7.4)
T1N1M0 1 1 2
T2N1M0 1 1 2
IIIA (9.2)
T1N2M0 1 — 1
T2N2M0 3 1 4
IIIB (7.4)
T4N0M0 2 1 3
T4N1M0 — 1 1
TNM, tumor node metastasis; TC, typical carcinoid; AC, atypical carcinoid.
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plastic procedures (40.8%) were performed with satisfactory
long-term results, in line with other authors.11,13,22 Confirm-
ing literature data,25 lymphadenectomy led to low morbidity
in our experience and neither fistula nor ischemic damage to
the airway was observed.
In TC, mediastinal relapses are quite rare and appear in
the long-term. Rea et al.28 observed two nodal relapses
(carinal and paratracheal) in patients in whom a systematic
nodal dissection was not performed. Bernstein et al.35 found
recurrences 18 and 32 years after pneumonectomy. El Jamal
et al.22 had one recurrence 18 years after surgery and empha-
sized the need for extraordinarily long follow-up to establish
the results of surgery. Consequently, we stress on the poten-
tially curative aspect of systematic nodal dissection in TC,
even if it will be difficult to prove in the near future the
impact upon the survival.
In AC, the lymphatic spread has been shown to be a
factor of worse prognosis as demonstrated by Garcia-Yuste
et al. Furthermore, they found a significant improvement
in patients’ survival with lymphatic spread between the
retrospective group (without systematic nodal dissection)
and the prospective group (following systematic nodal
dissection).29
Systematic nodal dissection plays a crucial role to
cure ACTH-secreting carcinoid as well. In Pass’s series of
13 patients, the first underwent a wedge resection without
lymphadenectomy and all subsequent patients underwent
systematic lymph node dissection in addition to the lobec-
tomy. Six of 13 patients had metastatic mediastinal lymph
nodes (46%) and among the 10 patients who became
eucortisolemic immediately after operation, five of them
were found to have positive lymph nodes (50%). Conse-
quently the author emphazises the curative aspect of “com-
pulsive” lymph node resection.36 In Shrager’s series of 7
patients, mediastinal lymphadenectomy was not systemati-
caly performed and 3 patients (43%) required a second
operation to resect metastatic lymph node relapses.37 Only
Deb et al.38 found a lower rate of lymph node metastases
(32%) and N2 disease (5.5%) in ACTH-secreting carci-
noids. However they concluded that these tumors should
be treated with formal anatomic resection and mediastinal
lymphadenectomy.
So far, in both groups of our series, all but one patient
with metastatic lymph nodes, including one case of ACTH-
secreting AC, are still alive and disease free. Furthermore we
did not find any significant survival difference according to
histologic type and nodal status. These results suggest the
role of systematic nodal dissection in survival’s improvement
in carcinoid tumors of the lung, even so we acknowledge the
limitation of this hypothesis in regard to the small number of
patients, mainly in AC, and the relatively short length of
follow-up. Some authors advocate for a bronchoscopic re-
moval associated with Nd-YAG laser, electrocautery39,40 or
cryotherapy41 to treat patients with intraluminal carcinoid in
a curative intent. In the van Boxem’s pilot study, tumor’s
eradication was effective in 14 of 19 patients (76.6%), with a
median follow-up of 29 months. In the remaining 5 patients,
radical resection was performed afterward with confirming
the presence of residual carcinoid of atypical feature, with
positive hilar node in one case, in contrast to the diagnosis
FIGURE 2. Kaplan-Meier curves:
survival in patients comparing
those without lymphatic spread
and those with lymphatic spread;
Log–rank p  0.518. LS, lymphatic
spread.
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ascertained before resection.39 Bertoletti et al.41 reported a
series of 19 patients treated with bronchoscopic removal plus
cryotherapy. Median follow-up was 55 months and a single
local recurrence (5.3%) was observed 7 years after the initial
treatment, requiring surgery for TC. Brokx et al. applied an
initial bronchoscopic treatment in 72 patients with intralumi-
nal bronchial carcinoids, to improve presurgical condition
and to enable less extensive parenchymal resection. Tumor
eradication was attempted in 35 of them, but not achieved in
two. In the other patients follow-up was stopped after the fifth
year and 2 of them showed late recurrence (100 months),
requiring further surgical resection.40 In these series, the
relatively short length of median follow-up (up to 55
months), in regard to late nodal relapse possibility even in
atypical feature,42 raises some doubt regarding the effective-
ness of bronchoscopic treatment in a curative intent. In our
series, among 10 patients showing “strictly endoluminal”
TC41 who were potentially eligible for bronchoscopic treat-
ment, surgery discovered N1 or N2 lymphatic spread in 2 of
them (20%) who were 29 and 15-year-old respectively (Table
3, patients n 3, 4). Accordingly, bronchoscopic treatment of
carcinoid should be restricted to elderly patients or patients
with a high operative risk. In other situations carcinoids
tumors demand a surgical treatment by lung resection with
bronchoplastic procedure whenever possible, associated with
systematic nodal dissection, as non-small cell bronchic car-
cinomas, even so the impact upon the survival is currently
difficult to estimate.
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